Lerociclib is a potential best-in-class oral CDK4/6 inhibitor being developed for use in combination with other targeted therapies in multiple oncology indications. Preliminary Phase 1b clinical data presented at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting, preclinical data presented at the American Association for Cancer Research Annual Meeting (2016-2018), and preclinical data published in Molecular Cancer Therapeutics and Oncotarget have demonstrated the compound’s differentiation from other CDK4/6 inhibitors.

Lerociclib is currently being evaluated in two Phase 1/2 clinical trials: a trial in combination with Faslodex® for patients with estrogen receptor-positive, HER2-negative breast cancer (NCT02983071), and a trial in combination with Tagrisso® in EGFRm non-small cell lung cancer (NCT03455829).